Geneva, June 22 -- International Clinical Trials Registry received information related to the study (ChiCTR2600126435) titled 'A prospective, randomized controlled, open-label, phase II clinical trial of Culmerciclib plus endocrine therapy versus mono-chemotherapy in HR+/HER2- advanced breast cancer with clinical aggressive disease criteria and high visceral tumor burden' on June 9.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Harbin Medical University Cancer Hospital

Condition: Advanced breast cancer

Intervention: Experimental group:Culmerciclib plus endocrine therapy

Recruitment Status: Not Recruiting

Phase: 2

Date of First Enrollment: 2026-06-09

Target Sample Size: Experimental group:70;Cont...